Compile Data Set for Download or QSAR
Report error Found 34 Enz. Inhib. hit(s) with all data for entry = 9593
TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476291(US10874675, Example 28)
Affinity DataEC50: <1.00E+3nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476281(US10874675, Example 20)
Affinity DataEC50: <250nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476282(US10874675, Example 21)
Affinity DataEC50: <250nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476283(US10874675, Example 22)
Affinity DataEC50: <250nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476284(US10874675, Example 23)
Affinity DataEC50: <250nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476285(US10874675, Example 24)
Affinity DataEC50: <250nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476287(US10874675, Example 25)
Affinity DataEC50: <250nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476288(US10874675, Example 26)
Affinity DataEC50: <500nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476289(US10874675, Example 27)
Affinity DataEC50: <500nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476280(US10874675, Example 19)
Affinity DataEC50: <250nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476292(US10874675, Example 29)
Affinity DataEC50: <1.00E+3nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476293(US10874675, Example 30)
Affinity DataEC50: <1.00E+3nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476294(US10874675, Example 31)
Affinity DataEC50: <1.00E+3nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476295(US10874675, Example 32)
Affinity DataEC50: <1.00E+3nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476296(US10874675, Example 33)
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476297(US10874675, Example 34)
Affinity DataEC50: >2.00E+3nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476298(US10874675, Example 35)
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476270(US10874675, Example 11)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476241(US10874675, Example 3)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476242(US10874675, Example 4)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476261(US10874675, Example 5)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476263(US10874675, Example 6)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476264(US10874675, Example 7)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476267(US10874675, Example 8)
Affinity DataEC50:  300nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476268(US10874675, Example 9)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476269(US10874675, Example 10)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476240(US10874675, Example 2)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476273(US10874675, Example 12)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476274(US10874675, Example 13)
Affinity DataEC50: <50nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476275(US10874675, Example 14)
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476276(US10874675, Example 15)
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476277(US10874675, Example 16)
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476278(US10874675, Example 17)
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandPNGBDBM476279(US10874675, Example 18)
Affinity DataEC50: <100nMAssay Description:Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
Go to US Patent